U.K., Oct. 2 -- DreaMed Diabetes, an AI-based remote diabetes solution, is to be made available in clinics across the US, with a particular focus on rural communities.
The new tool, which is the first of its kind to be approved by the FDA, is cloud-based and uses AI to monitor glucose levels as well as lifestyle habits, providing clinicians with an analysis of this patients data. Its aim is to enable clinicians to treat patients remotely, by providing a fast, accurate and thorough analysis. Research found its insulin management to be just as effective as treatment programmes managed by humans.
The Center for Disease Control and Prevention (CDC) estimates that 10% of the USA's adult population, or 34 million people have diabetes. The USA'...